Use of elexacaftor/tezacaftor/ivacaftor among cystic fibrosis lung transplant recipients

A CFTR Potentiator in Patients with Cystic Fibrosis and the <i>G551D</i> Mutation

Bonnie W. Ramsey, Jane C. Davies, Noel G. McElvaney et al. · New England Journal of Medicine · 2011 · 2.2K citations · Full text

Medicine, Molecular Biology, Molecular Genetics +8

Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

Peter G. Middleton, Marcus Mall, Pavel Dřevı́nek et al. · New England Journal of Medicine · 2019 · 2.1K citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +16

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

Harry Heijerman, Edward F. McKone, D.G. Downey et al. · The Lancet · 2019 · 1.4K citations · Full text

Life Sciences, Genetics, Pharmacology +14

Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial

American Journal of Respiratory and Critical Care Medicine · 2021 · 380 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study

Melena D. Bellin, Theresa A. Laguna, Janice Leschyshyn et al. · Pediatric Diabetes · 2013 · 193 citations

Medicine, Endocrinology, Pharmacology +17